Monoclonal Antibody Therapy tested for COVID-19
- This therapy is most suited for "high-risk COVID-19 patients" who are within the first 10 days of the symptom.
- Clinical parameters of two COVID-19 patients improved significantly within 12 hours of administering monoclonal antibody therapy,
- According to studies, this "antibody cocktail treatment" for COVID-19 can prevent case escalation from mild to moderate illness to severe, which then requires hospitalization in 70 percent of the cases.
Monoclonal Antibody Therapy
- Treatment that uses antibodies to help the body fight cancer, infection, or other diseases.
- Monoclonal antibodies (a type of antibody made in the laboratory) are identical copies of an antibody that targets one specific antigen like a corona virus.
- This treatment has previously been used to treat infections such as Ebola and HIV.
- The REGCov2 (Casirivimab and Imdevimab) is developed by Regeneron.